RMD - ResMed Inc.

NYSE - NYSE Delayed Price. Currency in USD
123.37
-0.38 (-0.31%)
At close: 4:01PM EDT

123.37 0.00 (0.00%)
After hours: 5:14PM EDT

Stock chart is not supported by your current browser
Previous Close123.75
Open123.94
Bid123.47 x 800
Ask126.02 x 1100
Day's Range122.75 - 124.15
52 Week Range90.64 - 124.94
Volume360,401
Avg. Volume576,156
Market Cap17.69B
Beta (3Y Monthly)0.34
PE Ratio (TTM)39.94
EPS (TTM)3.09
Earnings DateJul 25, 2019
Forward Dividend & Yield1.48 (1.20%)
Ex-Dividend Date2019-05-08
1y Target Est108.50
Trade prices are not sourced from all markets
  • Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways
    Zacks11 hours ago

    Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways

    Zacks.com featured highlights include: Carlisle, Northrop Grumman, ResMed, T. Rowe Price and JetBlue Airways

  • GlobeNewswire13 hours ago

    MatrixCare Appoints Geriatrician Dheeraj Mahajan as Chief Medical Officer, Executive Vice President

    MatrixCare announced today that Dheeraj Mahajan, MD, MBA, MPH, FACP, CMD, CIC, CHCQM, has joined its team as chief medical officer and executive vice president to advance MatrixCare’s vision of creating a seamless continuum where data moves with the patient, connecting both acute and post-acute care providers. Dr. Mahajan joins MatrixCare with more than 15 years as a practicing physician and is a nationally recognized expert and speaker on physician payment models, clinical documentation improvement, denial management, quality measurement in post-acute and long-term care, and transitional care quality improvement.

  • Business Wire2 days ago

    ResMed Inc. Completes $500M Private Placement Debt Offering

    ResMed Inc. (NYSE: RMD, ASX: RMD) announced today the successful pricing and closing of a private placement offering of $250,000,000 principal amount 3.24% senior notes due July 10, 2026, and $250,000,000 principal amount 3.45% senior notes due July 10, 2029. Net proceeds from the offering will be approximately $498 million, after deducting estimated fees and expenses related to the offering. The net proceeds will be used to pay down current borrowings on ResMed’s senior unsecured revolving credit facility.

  • GlobeNewswire2 days ago

    Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

    NEWPORT BEACH, Calif., July 15, 2019 -- Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a customer-centric approach focused on delivering breakthrough products,.

  • Add These 5 Stocks With Solid Sales Growth to Your Portfolio
    Zacks2 days ago

    Add These 5 Stocks With Solid Sales Growth to Your Portfolio

    Consistent growth in sales is the key to survival for any business.

  • Business Wire8 days ago

    The Lancet Publishes: More Than 936 Million Have Obstructive Sleep Apnea Worldwide

    More than 936 million people have obstructive sleep apnea – the disease’s first prevalence update in more than a decade – according to The Lancet Respiratory Medicine, the world’s leading journal in its field. The Lancet today published a multinational analysis by ResMed (RMD) (RMD.AX) and 12 academic leaders in sleep research. This figure is nearly 10 times greater than the World Health Organization’s 2007 estimate of more than 100 million, renewing calls for physicians to step up their efforts to screen, diagnose, and prescribe treatment for those who unknowingly suffer.

  • GuruFocus.com8 days ago

    Resmed Inc (RMD) CEO Michael J. Farrell Sold $823,128 of Shares

    CEO of Resmed Inc (NYSE:RMD) Michael J. Farrell sold 6,651 shares of RMD on 07/08/2019 at an average price of $123.76 a share.

  • ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite
    Zacks8 days ago

    ResMed (RMD) Rides on Strong SaaS Growth & New Product Suite

    ResMed's (RMD) new product menu and an array of strategies are likely to benefit from the sleep-disordered breathing market. This should further drive its short-term performance.

  • Business Wire14 days ago

    ResMed to Report Fourth Quarter Fiscal 2019 Earnings on July 25, 2019

    ResMed today announced it plans to release financial and operational results for the fourth quarter of fiscal year 2019 on Thursday, July 25, 2019, after the New York Stock Exchange closes.

  • Here’s What Hedge Funds Think About ResMed Inc. (RMD)
    Insider Monkey29 days ago

    Here’s What Hedge Funds Think About ResMed Inc. (RMD)

    Is ResMed Inc. (NYSE:RMD) a good equity to bet on right now? We like to check what the smart money thinks first before doing extensive research. Although there have been several high profile failed hedge fund picks, the consensus picks among hedge fund investors have historically outperformed the market after adjusting for known risk attributes. […]

  • TheStreet.comlast month

    ResMed Could Rally Another 25% From Here

    During Friday night's Lightning Round of Mad Money, Jim Cramer said this about ResMed Inc. In the daily bar chart of RMD, below, we can see a wide-swinging sideways market for this stock. The daily On-Balance-Volume (OBV) line has been steady from March, and is close to making a new high for the move up.

  • Why We Like ResMed Inc.’s (NYSE:RMD) 17% Return On Capital Employed
    Simply Wall St.last month

    Why We Like ResMed Inc.’s (NYSE:RMD) 17% Return On Capital Employed

    Today we are going to look at ResMed Inc. (NYSE:RMD) to see whether it might be an attractive investment prospect. In...

  • Business Wirelast month

    New Analysis Shows Sleep Apnea More Common in Americas than Previously Thought

    ResMed (RMD) (RMD.AX) revealed roughly 170 million people across North and South America have sleep apnea, according to a study it presented at the annual SLEEP meeting hosted by the American Academy of Sleep Medicine (AASM) and the Sleep Research Society.

  • Markitlast month

    See what the IHS Markit Score report has to say about ResMed Inc.

    ResMed Inc NYSE:RMDView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for RMD with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding RMD totaled $6.23 billion. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.

  • ResMed (RMD) Up 7.2% Since Last Earnings Report: Can It Continue?
    Zacks2 months ago

    ResMed (RMD) Up 7.2% Since Last Earnings Report: Can It Continue?

    ResMed (RMD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Does ResMed Inc.'s (NYSE:RMD) Past Performance Indicate A Stronger Future?
    Simply Wall St.2 months ago

    Does ResMed Inc.'s (NYSE:RMD) Past Performance Indicate A Stronger Future?

    Measuring ResMed Inc.'s (NYSE:RMD) track record of past performance is an insightful exercise for investors. It...

  • Business Wire2 months ago

    ResMed Appoints New South Asia General Manager to Help Drive Increased Awareness and Treatment of Sleep Apnea, Other Respiratory Diseases

    ResMed, a world leader in connected health solutions for sleep apnea, lung disease, and other chronic diseases, today announced the appointment of Shubhi Khurana as general manager for India and South Asia.

  • Business Wire2 months ago

    ResMed Announces Participation in the 40th Annual Goldman Sachs Global Healthcare Conference

    ResMed today announced that Rob Douglas, president and chief operating officer, will participate in a fireside chat discussion at the 40th Annual Goldman Sachs Global Healthcare Conference on Tuesday, June 11, 2019, beginning at approximately 10:00 a.m.

  • Business Wire2 months ago

    ResMed Announces Participation in the 39th Annual William Blair Growth Stock Conference

    ResMed today announced that Mick Farrell, chief executive officer, will present at the 39th Annual William Blair Growth Stock Conference on Thursday, June 6, 2019, beginning at approximately 8:40 a.m.

  • ResMed Study Shows Remote Monitoring Benefits on CPAP Use
    Zacks2 months ago

    ResMed Study Shows Remote Monitoring Benefits on CPAP Use

    Results of this study mark a remarkable feat for ResMed's (RMD) medical innovation aimed at treating people suffering from sleep apnea.

  • Business Wire2 months ago

    ResMed Study Finds CPAP Adherence Improved by Remote Monitoring, Self-Monitoring across 3 Countries

    .@ResMed study finds #CPAP adherence improved by remote monitoring, self-monitoring across 3 countries

  • Business Wire2 months ago

    Age, Gender, Disease Severity Impact Adherence to Long-Term PAP Therapy More Than Previously Thought

    Age, gender, and disease severity all impact long-term #CPAP adherence more than previously thought, according to a million-patient study shown at #ATS2019 #sleepapnea

  • Business Wire2 months ago

    ResMed Elects Jan De Witte to Its Board of Directors

    ResMed (NYSE: RMD, ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital SaaS solutions, today announced it has elected experienced business executive Jan De Witte to its board of directors. Mr. De Witte was appointed during ResMed’s regularly scheduled board meeting on May 16, 2019, to fill a newly created directorship, effective immediately.

  • Here's Why You Should Hold on to ResMed (RMD) Stock for Now
    Zacks2 months ago

    Here's Why You Should Hold on to ResMed (RMD) Stock for Now

    ResMed (RMD) continues to see strong sales from SaaS business as well as new mask products and devices.

  • What does ResMed Inc.'s (NYSE:RMD) Balance Sheet Tell Us About Its Future?
    Simply Wall St.2 months ago

    What does ResMed Inc.'s (NYSE:RMD) Balance Sheet Tell Us About Its Future?

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift...